Abstract: Reducing the frequency of pulmonary exacerbations in patients suffering from Non-Cystic Fibrosis Bronchiectasis (NCFB) by administering colistin is described.

Abstract: The present invention relates to the use of Colistin for reducing the frequency of pulmonary exacerbations in patients suffering from Non-Cystic Fibrosis Bronchiectasis (NCFB), wherein said patients are infected with P. aeruginosa.

Abstract: A synergistic pharmacological association of N-acetylcysteine (NAC) and colistin for use in the treatment of a bacterial infection caused by one or more pathogens selected from S. maltophilia and A. baumannii strains, in particular a bacterial infection associated with a respiratory tract disease, such as a chronic respiratory tract disease comprising cystic fibrosis (CF), bronchiectasis non CF and chronic obstructive pulmonary disease COPD is described.

Abstract: The present invention relates to a synergistic pharmacological antibiofilm association of colistin and fosfomycin for use in the treatment of a bacterial infection caused by a biofilm-forming pathogen selected from A. baumannii, P. aeruginosa, S. maltophilia and K. pneumoniae strains, preferably in the biofilm phase of growth and, in particular infections associated with a respiratory tract disease, such as a chronic respiratory tract disease comprising CF, NCFB and COPD, especially in hospitalized patients.

Abstract: The present invention relates to N-acetylcysteine for the use in the treatment of bacterial infections caused by a pathogen selected from Burkholderia cepacia complex (BCC) and Stenotrophomonas maltophilia (S. maltophilia) strains.

Abstract: The present invention relates to safmamide or a pharmaceutically acceptable salt thereof for use in the treatment of a condition caused by pathological sarcolemma hyperexcitability, and/or of any other condition in which the restoration of normal sarcolemma excitability may produce a therapeutic benefit or improvement, wherein said condition is preferably a myotonic disorder.

Abstract: The present invention relates to the use of Colistin for reducing the frequency of pulmonary exacerbations in patients suffering from Non-Cystic Fibrosis Bronchiectasis (NCFB), wherein said patients are infected with P. aeruginosa.

Abstract: A synergistic pharmacological association of N-acetylcysteine (NAC) and colistin for use in the treatment of a bacterial infection caused by one or more pathogens selected from S. maltophilia and A. baumannii strains, in particular a bacterial infection associated with a respiratory tract disease, such as a chronic respiratory tract disease comprising cystic fibrosis (CF), bronchiectasis non CF and chronic obstructive pulmonary disease COPD is described.

Abstract: The present invention relates to pharmaceutical compositions comprising safinamide and, more particularly, to taste-masked particles comprising said active ingredient or pharmaceutically acceptable salts thereof, oral dosage forms that include said particles and a process for preparing them.

Abstract: The present invention relates to safmamide or a pharmaceutically acceptable salt thereof for use in the treatment of a condition caused by pathological sarcolemma hyperexcitability, and/or of any other condition in which the restoration of normal sarcolemma excitability may produce a therapeutic benefit or improvement, wherein said condition is preferably a myotonic disorder.

Abstract: The present invention relates to a synergistic pharmacological association of NAC and colistin for use in the treatment of a bacterial infection caused by one or more pathogens selected from S. maltophilia and A. baumannii strains, in particular a bacterial infection associated with a respiratory tract disease, such as a chronic respiratory tract disease comprising CF, bronchiectasis non CF and COPD.

Abstract: The present invention relates to N-acetylcysteine for the use in the treatment of bacterial infections caused by a pathogen selected from Burkholderia cepacia complex (BCC) and Stenotrophomonas maltophilia (S. maltophilia) strains.

Abstract: A pharmaceutical, non-effervescent, solid composition comprising a mixture of a pharmaceutically effective amount of a ibuprofen salt and a pharmaceutically acceptable strong base in a molar ratio of from 1:0.01 to 1:0.8, said composition being such that, when dissolved in drinkable water for dilution, imparts a pH value ranging from 9 to 9.5 to the obtained solution, which do not cause sensory irritation to the oral cavity especially to the back of the mouth and throat, when swallowed.

Abstract: The present invention relates to pharmaceutical compositions comprising safinamide and, more particularly, to taste-masked particles comprising said active ingredient or pharmaceutically acceptable salts thereof, oral dosage forms that include said particles and a process for preparing them.

Abstract: The present invention relates to pharmaceutical compositions comprising safinamide, and, more particularly, to taste-masked particles comprising said active ingredient or pharmaceutically acceptable salts thereof, oral dosage forms that include said particles and a process for preparing them.

Abstract: The present invention relates to N-acetylcysteine for the use in the treatment of bacterial infections caused by a pathogen selected from Burkholderia cepacia complex (BCC) and Stenotrophomonas maltophilia (S. maltophilia) strains.

Abstract: The present invention relates to pharmaceutical compositions comprising safinamide, and, more particularly, to taste-masked particles comprising said active ingredient or pharmaceutically acceptable salts thereof, oral dosage forms that include said particles and a process for preparing them.

Abstract: The present invention relates to inhalation formulations of drugs in the form of dry powder for inhalation administration deliverable as such with an inhaler and provided with high deliverability, respirability and stability. In particular, the invention relates to a pharmaceutical composition for inhalation in the form of powder comprising at least a first and a second powder, in which at least said first powder contains an active agent in an amount greater than 1% by weight with respect to the weight of said first powder. Both the powders comprise leucine in an amount ranging from 5 to 70% by weight with respect to the weight of each powder and a sugar in an amount ranging from 20 to 90% by weight with respect to the weight of each powder. The composition has a fine particle fraction (FPF) greater than 60% and a delivered fraction (DF) greater than 80.

Abstract: The present invention relates to inhalation formulations of drugs in the form of dry powder for inhalation administration deliverable as such with an inhaler and provided with high deliverability, respirability and stability. In particular, the invention relates to a pharmaceutical composition for inhalation use in powder form comprising a first powder comprising at least a powder (a1) comprising an active agent or a pharmaceutically acceptable salt thereof, in an amount greater than 1% by weight of the powder, leucine in an amount from 5 to 70% by weight of said powder, a sugar in an amount from 20 to 90% by weight of the powder; and a second powder comprising a mixture of a first lactose which has an X50 from 35 to 75 ?m, with a second lactose which has an X50 from 1.5 to 10 ?m, the content of the first and second lactose in the mixture are respectively from 85% to 96% and from 4% to 15%.

Abstract: The present invention relates to inhalation formulations of drugs in the form of dry powder for inhalation administration, suitable for the treatment of obstructive diseases of the airways, such as asthma and chronic obstructive pulmonary disease (COPD).